Alector/ALEC

$5.09

1.38%
-
1D1W1MYTD1YMAX

About Alector

Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.

Ticker

ALEC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Arnon Rosenthal

Employees

244

Headquarters

South san francisco, United States

Alector Metrics

BasicAdvanced
$540.03M
Market cap
-
P/E ratio
-$1.56
EPS
0.79
Beta
-
Dividend rate
$540.03M
0.79129
$9.07
$3.66
728.56K
3.18
-18.5%
-74.81%
-22.92%
5.564
3.568
4.025
-27.36%
3.69%
66.32%

What the Analysts think about Alector

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 8 analysts.
184.87% upside
High $41.00
Low $4.00
$5.09
Current price
$14.50
Average price target

Alector Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-274.17% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$15.1M
65.93%
Net income
$-41.4M
-6.76%
Profit margin
-274.17%
-43.81%

Alector Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 36.44%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.55
$0.02
-$0.53
-$0.49
-
Expected
-$0.76
-$0.82
-$0.66
-$0.77
-$0.51
Surprise
-27.54%
-102.44%
-19.36%
-36.44%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Alector stock?

Alector (ALEC) has a market cap of $540.03M as of April 19, 2024.

What is the P/E ratio for Alector stock?

The price to earnings (P/E) ratio for Alector (ALEC) stock is 0 as of April 19, 2024.

Does Alector stock pay dividends?

No, Alector (ALEC) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Alector dividend payment date?

Alector (ALEC) stock does not pay dividends to its shareholders.

What is the beta indicator for Alector?

Alector (ALEC) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Alector stock price target?

The target price for Alector (ALEC) stock is $14.5, which is 184.87% above the current price of $5.09. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Alector stock

Buy or sell Alector stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing